What is a stock summary page? Click here for an overview.
Business Description
Nurix Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US67080M1036
Share Class Description:
NRIX: Ordinary SharesDescription
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 21.54 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.41 | |||||
| Beneish M-Score | -3.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.4 | |||||
| 3-Year EBITDA Growth Rate | -4 | |||||
| 3-Year EPS without NRI Growth Rate | -1.8 | |||||
| 3-Year FCF Growth Rate | -8.9 | |||||
| 3-Year Book Growth Rate | -3.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -4.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 15.04 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.67 | |||||
| 9-Day RSI | 28.69 | |||||
| 14-Day RSI | 30.68 | |||||
| 3-1 Month Momentum % | -19.15 | |||||
| 6-1 Month Momentum % | -32.97 | |||||
| 12-1 Month Momentum % | 5.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.46 | |||||
| Quick Ratio | 6.46 | |||||
| Cash Ratio | 6.36 | |||||
| Days Sales Outstanding | 13.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.3 | |||||
| Shareholder Yield % | -53.39 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -390.52 | |||||
| Net Margin % | -354.85 | |||||
| FCF Margin % | -333.38 | |||||
| ROE % | -58.88 | |||||
| ROA % | -40.97 | |||||
| ROIC % | -169.38 | |||||
| 3-Year ROIIC % | 90.78 | |||||
| ROC (Joel Greenblatt) % | -458 | |||||
| ROCE % | -55.34 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 14.48 | |||||
| PB Ratio | 1.75 | |||||
| Price-to-Tangible-Book | 1.75 | |||||
| EV-to-EBIT | -1.6 | |||||
| EV-to-Forward-EBIT | -1.16 | |||||
| EV-to-EBITDA | -1.73 | |||||
| EV-to-Forward-EBITDA | -1.19 | |||||
| EV-to-Revenue | 6.25 | |||||
| EV-to-Forward-Revenue | 5.74 | |||||
| EV-to-FCF | -1.87 | |||||
| Price-to-GF-Value | 1.18 | |||||
| Price-to-Net-Current-Asset-Value | 1.93 | |||||
| Price-to-Net-Cash | 1.97 | |||||
| Earnings Yield (Greenblatt) % | -62.5 | |||||
| FCF Yield % | -19.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NRIX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nurix Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 54.549 | ||
| EPS (TTM) ($) | -2.89 | ||
| Beta | 1.94 | ||
| 3-Year Sharpe Ratio | 0.25 | ||
| 3-Year Sortino Ratio | 0.47 | ||
| Volatility % | 64.73 | ||
| 14-Day RSI | 30.68 | ||
| 14-Day ATR ($) | 0.856962 | ||
| 20-Day SMA ($) | 13.557 | ||
| 12-1 Month Momentum % | 5.1 | ||
| 52-Week Range ($) | 11.9 - 29.56 | ||
| Shares Outstanding (Mil) | 75.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nurix Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nurix Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nurix Therapeutics Inc Frequently Asked Questions
What is Nurix Therapeutics Inc(NRIX)'s stock price today?
The current price of NRIX is $12.15. The 52 week high of NRIX is $29.56 and 52 week low is $11.90.
When is next earnings date of Nurix Therapeutics Inc(NRIX)?
The next earnings date of Nurix Therapeutics Inc(NRIX) is 2025-04-10 Est..
Does Nurix Therapeutics Inc(NRIX) pay dividends? If so, how much?
Nurix Therapeutics Inc(NRIX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers